(Total Views: 570)
Posted On: 11/08/2021 6:01:13 AM
Post# of 145247
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
CytoDyn Submits Breakthrough Therapy Designation Application to FDA for Leronlimab as a Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC); Fast Track Designation for mTNBC was received previously
https://www.cytodyn.com/newsroom/press-releas...esignation
https://www.cytodyn.com/newsroom/press-releas...esignation
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)